- Coordinator
- Charite - Universitaetsmedizin Berlin, Germany
- Runs
- 1 January 2023 to 31 December 2026
- Status
- Running
- EU funding
- €6.2m
- Total cost
- €6.2m
- Partners
- 13 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101095540
What the project is doing
In the project's own words, from its summary on CORDIS.
IMMEDIATE aims to investigate and explore the diet-microbiome-immunometabolism-axis as a sensor for health-to-disease transition and evaluate strategies to maintain an individual’s well-being. Chronic inflammation is the major root of most diseases. Understanding of this process preceding organ dysfunction or damage and identification of biomarkers in the pre-symptomatic stage and risk but also resilience factors of health-to-disease transition will enable targeted and personalized interventions to prevent irreversible organ damage.
Metabolites of gut microbiota are key messengers between diet, microbiota and host, maintaining the balance of pro- and anti-inflammation. Our study takes advantage of cutting-edge omics technologies available within the IMMEDIATE consortium in conjunction with available clinical data and biospecimens from ongoing observational studies, enrolling “healthy” subjects and individuals in the pre-disease stage but with largely distinct environmental and dietary modulators, including a cohort of kidney transplant recipients in whom renal function has been “reset to baseline”.
The identification of clinical and omics-derived biomarkers will – by employing AI algorithms - yield a personalized risk / resilience score of chronic inflammation and thus a better prediction of an individual’s risk of transition towards disease. A proof-of-concept intervention study with the anti-inflammatory microbe Akkermansia muciniphila will be conducted to test whether deflections of the microbiome-metabolite-immune axis can be reverted on the biomarker level but also with respect to clinical outcomes and overall well-being.
Mobile apps developed by the IMMEDIATE consortium in collaboration with patient organizations tracking numerous lifestyle-related measures and providing guidance and feedback on these aspects will empower individuals to adopt and integrate these knowledge-based health interventions into their own lives, hereby self-managing their own health.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Coordinator |
| The Akkermansia Company | Ottignies-Louvain-la-Neuve | Belgium | Participant |
| Bundesverband Niere E.v. | Mainz | Germany | Participant |
| Eurice European Research and Project Office GmbH | St Ingbert | Germany | Participant |
| Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (mdc) | Berlin | Germany | Participant |
| Universitaetsklinikum Essen | Essen | Germany | Participant |
| Universitatsklinikum Erlangen | Erlangen | Germany | Participant |
| Research and Innovation Services Doo Za Usluge | Zagreb | Croatia | Third party |
| Weizmann Institute of Science | Rehovot | Israel | Participant |
| Zadig SRL | Milano | Italy | Participant |
| Pomorski Uniwersytet Medyczny W Szczecinie | Szczecin | Poland | Participant |
| Sanprobi Spolka Z Ograniczona Odpowiedzialnoscia Spolka Komandytowa | Szczecin | Poland | Participant |
| Imperial College of Science Technology and Medicine | London | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI